T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment (Q39300005)

10 September 2017

title

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment (English)

1 reference

10 September 2017

0 references

16

Tanja D de Gruijl

1 reference

10 September 2017

author name string

Saskia J A M Santegoets

1

1 reference

10 September 2017

Anita G M Stam

2

1 reference

10 September 2017

Sinéad M Lougheed

3

1 reference

10 September 2017

Helen Gall

4

1 reference

10 September 2017

Petra E T Scholten

5

1 reference

10 September 2017

Martine Reijm

6

1 reference

10 September 2017

Karin Jooss

7

1 reference

10 September 2017

Natalie Sacks

8

1 reference

10 September 2017

Kristen Hege

9

1 reference

10 September 2017

Israel Lowy

10

1 reference

10 September 2017

Jean-Marie Cuillerot

11

1 reference

10 September 2017

B Mary E von Blomberg

12

1 reference

10 September 2017

Rik J Scheper

13

1 reference

10 September 2017

Alfons J M van den Eertwegh

14

1 reference

10 September 2017

Winald R Gerritsen

15

1 reference

10 September 2017

publication date

10 August 2012

1 reference

Cancer Immunology, Immunotherapy

10 September 2017

published in

1 reference

10 September 2017

volume

62

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

245-256

1 reference

10 September 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Prostate cancer as a model for tumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

21 January 2018

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Autoimmunity and treatment outcome in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1330-5

10.1007/S00262-012-1330-5

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference